They proudly served their adoptive nation – and found a path to medicine along the way
When Jose Chevalier, Isabelle Trinh Phan and Nam Yong Cho enlisted in the U.S. military, they were thinking of their families. Their families were, after all, the strongest support system these three Bruins had after immigrating to the U.S. from various parts of the globe, and joining up meant easing the pressure on their loved ones. But it was a good thing for a variety of reasons.While none of these student veterans could have predicted it, their military experiences would also point them toward academic and career trajectories in medicine, eventually leading two of them to theDavid Geffen School of Medicine at UCLA and ...
Source: UCLA Newsroom: Health Sciences - November 9, 2023 Category: Universities & Medical Training Source Type: news
Combined ultrasound, MRI characterizes nonmass-like breast lesions
Combining ultrasound with MRI could help better differentiate between benign and malignant breast nonmass-like lesions initially detected on ultrasound, a study published October 12 in Ultrasound in Medicine & Biology found. Researchers led by Rui-Lan Niu, PhD, from the Chinese PLA General Hospital in Beijing, China, found that their combined method led to improved performance in this area over each modality alone.
“The study determined that the integrated diagnostic strategy had good performance in the diagnosis of nonmass-like lesions, which can improve diagnostic specificity while maintaining high sensitivity,” Ni...
Source: AuntMinnie.com Headlines - October 13, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Clinical News Womens Imaging Breast Source Type: news
Behavior Is a Miracle Drug for Our Health
Healthcare is broken. Chronic diseases are eating up an increasing share of healthcare resources in every healthcare system across the world in ways that are not sustainable. Yes, there is a golden age of innovation happening in the form of new technologies like gene therapy, neural technology, immunotherapy, and increasingly the impact of AI on diagnoses and drug development, but we can’t let these extraordinary technological advances blind us to the tragedy of modern healthcare and to the much neglected miracle drug right in front of us: our daily behaviors. Whether for preventing disease or optimizing the treatmen...
Source: TIME: Health - August 31, 2023 Category: Consumer Health News Authors: Arianna Huffington Tags: Uncategorized freelance Source Type: news
Antithrombotic therapy safe to continue during breast biopsy
Women can safely continue antithrombotic therapy during breast core-needle biopsy...Read more on AuntMinnie.comRelated Reading:
USPSTF calls for biennial mammography screening as of age 40
SBI: The presence of LCIS indicates increased breast cancer risk
Mammo-guided vacuum-assisted biopsy effective for thin breast tissue
SBI: DCIS progression appears as new masses on surveillance imaging
ACR releases updated breast cancer screening recommendation (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 11, 2023 Category: Radiology Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Afghan Moms Receive a Fresh Start in the United States
Credit: UNHCRBy Lori Silberman BraunerTEANECK, New Jersey, Apr 26 2022 (IPS) It was a long, harrowing road for Freshta and Shabaneh, two mothers (their names are pseudonyms) who fled Kabul, Afghanistan, late last summer before eventually settling in the southern New Jersey township of Hamilton.
Shabaneh, 30, the mother of three boys who was then between four and five months pregnant, recalls her flight out of Kabul’s Hamid Karzai International Airport on a U.S. army plane under less-than-optimal conditions.
Whatever seats had been in place had been removed from the plane to accommodate all the passengers, and she had n...
Source: IPS Inter Press Service - Health - April 26, 2022 Category: International Medicine & Public Health Authors: Lori Silberman Brauner Tags: Aid Armed Conflicts Asia-Pacific Development & Aid Education Gender Headlines Health Human Rights Labour TerraViva United Nations IPS UN Bureau Source Type: news
What Percentage of Breast Needle Biopsies Are Cancer?
Title: What Percentage of Breast Needle Biopsies Are Cancer?Category: Diseases and ConditionsCreated: 4/6/2022 12:00:00 AMLast Editorial Review: 4/6/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 6, 2022 Category: Cancer & Oncology Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bringing WISDOM to Breast Cancer Care
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - October 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
